Syntaxin's Board of Directors
Andrew Sandham, Non-Executive Chairman
Abingworth Management
Andrew has 28 years of experience in the healthcare sector, in a broad spectrum of roles covering corporate strategy, operational management, business development and marketing... Read full profile
Andrew has 28 years of experience in the healthcare sector, in a broad spectrum of roles covering corporate strategy, operational management, business development and marketing. During this time, he has contributed significantly to the establishment of successful drug discovery and development companies both in Europe and the USA. Before joining Abingworth Management, Andrew was Chief Executive Officer and co-founder of Ionix Pharmaceuticals, which was divested to Vernalis plc in 2005. Prior to this he served as Chief Operating Officer of Signature BioScience, Hexagen and Cantab Pharmaceuticals. He has also held business development and marketing positions at Amersham, Celltech and Roche. Andrew is currently non-executive Chairman of NeurAxon and Novacta Biosystems. He has a BSc in Chemistry from University of East Anglia and a Diploma in Marketing from the Institute of Marketing.
Minimise profile
James Abell
Abingworth Management
James is a Partner of Abingworth LLP and its Chief Financial Officer, and his directorships of Abingworth portfolio companies have included Chroma Therapeutics and Clinical Designs. Read full profile
James is a Partner of Abingworth LLP and its Chief Financial Officer, and his directorships of Abingworth portfolio companies have included Chroma Therapeutics and Clinical Designs. Before joining Abingworth in 1997 he was Chief Financial Officer of Prolifix Ltd and a director of Cambridge Genetics. From 1994 to 1996 he worked as a consultant for the Medical Research Council, where he advised the founders of start-up biotechnology companies. He qualified as a Chartered Accountant with KPMG and worked there from 1983 to 1993. He has a degree in biology with chemistry from Southampton University.
Minimise profile
Patrick Doyle, Chief Executive Officer
Syntaxin
Patrick joined Syntaxin in August 2006 as CEO. He brings 17 years of broad pharmaceutical experience to Syntaxin, most recently serving as Chief Corporate Development Officer for Metabolex... Read full profile
Patrick joined Syntaxin in August 2006 as CEO. He brings 17 years of broad pharmaceutical experience to Syntaxin, most recently serving as Chief Corporate Development Officer for Metabolex, San Francisco. Since early 2005 he led Metabolex' corporate development activities, which resulted in a global partnership with Johnson & Johnson. Prior to that Patrick was Roche's Vice President, Global Head of Preclinical Partnering and a member of Roche's Research and Development Committee. While at Roche, Patrick established and implemented the company's global external preclinical, research and technology strategy and led a team of executives to identify, execute and manage diverse preclinical and late-stage deals, including the integration of Chugai's late-stage portfolio into the global Roche Group. Earlier in his career he worked at Novo Nordisk as a scientific coordinator. Patrick received his BSc (Hons) in Pharmacology and studied for a PhD at the University of Sunderland in England. He also completed post-graduate studies at the University of Geneva, where he specialized in CNS function.
Minimise profile
Dr Deborah Harland
S.R. One
Dr Harland joined SR One in 2005, is based in the UK and leads SR One's activities in Europe. Deborah is a member of the Board of Directors of Addex Pharmaceuticals SA and PharmaKodex... Read full profile
Dr Harland joined SR One in 2005, is based in the UK and leads SR One's activities in Europe. Deborah is a member of the Board of Directors of Addex Pharmaceuticals SA and PharmaKodex and is an observer on the boards of 7TM, Ablynx NV and Resistentia Pharmaceuticals AB. Prior to SR One, Deborah was part of GSK's Worldwide Business Development team where she was responsible for sourcing and evaluating in-licensing opportunities in the Psychiatry, Neurology and Gastrointestinal therapeutic areas. During her time with Business Development Deborah led due diligence teams associated with successful in-licensing of preclinical and marketed products as well as a multiple-asset research and development collaboration. Prior to that Deborah held positions of increasing responsibility within SmithKline Beecham's development organisation covering clinical development, medical affairs, medical communications, medical marketing and business development support. She holds a BSc. (Hons.) in Pharmacology from the University of Bath, a PhD in Pharmacology from the University of London, and an MBA from Henley Management College.
Minimise profile
Dr René Kuijten
LSP
Dr René Kuijten, MD PhD MBA, joined LSP in early 2001 as a general partner. He serves or has served on the supervisory boards of KuDOS (UK, acquired by AstraZeneca in 2005), DNage (NL, acquired by Pharming in 2006)... Read full profile
Dr René Kuijten, MD PhD MBA, joined LSP in early 2001 as a general partner. He serves or has served on the supervisory boards of KuDOS (UK, acquired by AstraZeneca in 2005), DNage (NL, acquired by Pharming in 2006), OctoPlus (NL, IPO Euronext 2006), Kreatech (NL), Hybrigenics (F), BMEYE (NL) and Trinity (US) and has led LSP's investments in Morphochem (G, acquired by Biovertis in 2005) and Zealand Pharma (DK). René is also jury member of New Venture, a business plan competition; board member of the McKinsey Alumni Association and the Max Geldens Society for societal renewal; and board member of the NVP, the Dutch Venture Capital Association, chairing the committee for institutional investors. He recently was a member of the Royal Dutch Academy of Sciences committee, advising the Dutch government on gene patenting. From 1992-2000, René was a senior manager at McKinsey & Company in Amsterdam, Brussels and Zurich, and co-leader of the European Pharmaceuticals and Health Care Practice. In this capacity, he advised the management boards of several multinational companies on strategy, M&A, performance improvement and restructuring. René was trained as a Medical Doctor at the University of Utrecht, Harvard Medical School and the Mayo Clinics. He completed his PhD studies at the University of Pennsylvania Cancer Center and published in medical journals as the New England Journal of Medicine and Cancer Research. He has received research awards from the World Health Organization and the International Union Against Cancer, and the Talma Eijkman Prize and the U-Gene Research Award for his scientific endeavors. He obtained his MBA degree from INSEAD in Fontainebleau, France.
Minimise profile
Zeev Zehavi
JJDC
Zeev Zehavi started with the Johnson & Johnson Development Corporation as a Vice President in October 1999. Zeev is headquartered in Tel Aviv, and is responsible for the venture capital investments in Europe and Israel... Read full profile
Zeev Zehavi started with the Johnson & Johnson Development Corporation as a Vice President in October 1999. Zeev is headquartered in Tel Aviv, and is responsible for the venture capital investments in Europe and Israel. Zeev's background covers an extensive array of health care and health care related businesses. He spent over ten years with Teva Pharmaceuticals, including a five-year assignment as President of the bulk chemical business in North America. Following that experience with Teva in the United States, Zeev returned to Israel as President of Clal Pharmaceutical industries for four years before starting his own consulting business as Pharma Zee Ltd. During this consulting business for medical devices and pharmaceutical start-up companies, he actually initiated contacts with various Johnson & Johnson companies. Zeev is fluent in Hebrew, English and Arabic. He holds a BS degree from Hebrew University of Jerusalem, as well as a MBA in Marketing and Finance from Tel Aviv University.
Minimise profile
Dr. Eduard Enrico Holdener, Non-Executive Director
Independent
Dr Holdener has over 20 years of international pharmaceutical senior executive experience and was most recently Chief Medical Officer of F. Hoffman-La Roche's Pharma Division... Read full profile
Dr Holdener has over 20 years of international pharmaceutical senior executive experience and was most recently Chief Medical Officer of F. Hoffman-La Roche's Pharma Division. He was also Global Head of Pharmaceutical Drug Development at Roche where he was instrumental in establishing and expanding Roche's therapeutic areas and in achieving several key international approvals for oncology, rheumatology, and virology drugs such as MabThera. He also led Roche's development operations in Japan for three years and was a member of the Chugai Co. acquisition and integration team during the Roche/Chugai merger in 2001. Dr Holdener holds a medical degree from the University of Zurich and completed a two year clinical and experimental fellowship in oncology at the University of Kansas Medical School, USA.
Minimise profile